BIO-Europe 2026 has ended. This guide stays up as the record of who was there. See upcoming conferences
Investors at BIO‑Europe 2026
Nov 9–11, 2026 Cologne, Germany ~5.8k attendees Website
51 investors are at BIO-Europe 2026 — 58 presentations on the program. Most represented: Sofinnova Partners (4 on the program), Jeito Capital (3 on the program), Andera Partners (2 on the program). 43 of them have their own page in this guide. As of Nov 10, 2026.
Track
Top represented
Showing 1–15 of 51 organizations
| Organization | BIO-Europe 2026 Attendance |
|---|---|
Sofinnova Partners Paris, France | |
Life sciences venture capital firm investing from seed to late stage in biotech, medtech and industrial biotech. | Panel Mon Nov 9 16:00–16:45 Cell and Gene Therapy: What Should You Know? Where gene therapies stand across diseases, and what shifting funding and partnerships mean for regulation, manufacturing, investment and market access. Panel Mon Nov 9 16:00–16:45 Fuelling Innovation: The State of Early-Stage Investment in Biotech Investors and founders discuss how young biotech startups raise early funding today and how venture investors' priorities are shifting. Panel Tue Nov 10 15:00–15:45 Scaling Success: The Dynamics of Late-Stage Investment in Biotech How investors back biotechs whose products are close to market, from regulatory hurdles and scaling up to going public or being acquired. |
Jeito Capital Paris, France | |
Paris-based private equity investor financing biotech and medical innovation companies. | Panel Tue Nov 10 16:00–16:45 At the Board Table: Navigating Power Dynamics and Building Senior Stakeholder Trust (In collaboration with YVC) How younger executives and junior investors on biotech boards can earn senior members' trust and help drive decisions. Panel Tue Nov 10 15:00–15:45 Scaling Success: The Dynamics of Late-Stage Investment in Biotech How investors back biotechs whose products are close to market, from regulatory hurdles and scaling up to going public or being acquired. |
Andera Partners Paris, France | |
Private equity firm whose life sciences team invests in biotech and medtech companies through its BioDiscovery funds. | Keynote Mon Nov 9 12:00–13:00 Building a competitive and impactful European biotech community: Perspectives from the European Life Sciences Coalition, Argenx and Tubulis How Europe can keep biotech talent, money and companies at home by drawing in big investors, speeding regulation and building stronger stock markets. Ecosystem InnovationBusiness of Biotech Panel Mon Nov 9 14:00–14:45 Voices from the IPO Class of ’25/’26: What’s Next? Leaders of biotechs that listed on the stock market in 2025 and 2026 describe life after going public and the hurdles they face. |
AV Angelini Ventures Rome, Italy | |
Corporate venture capital arm of Angelini Industries, investing in biotech, medtech and digital health companies. | Keynote Mon Nov 9 12:00–13:00 Building a competitive and impactful European biotech community: Perspectives from the European Life Sciences Coalition, Argenx and Tubulis How Europe can keep biotech talent, money and companies at home by drawing in big investors, speeding regulation and building stronger stock markets. Ecosystem InnovationBusiness of Biotech Panel Tue Nov 10 17:00–17:45 Resilient by Design: Reinventing Biopharma Alliances in a Fragmenting World How drug companies are reshaping research and manufacturing partnerships to stay reliable as political tensions and supply chain risks divide the world. Business of BiotechBiomanufacturing Strategy |
Italian venture capital firm investing in early-stage biotech companies. | Panel Tue Nov 10 14:00–14:45 Immunology under the microscope: New frontiers What is new in drugs for autoimmune and inflammatory diseases: emerging targets, recent trial results, and where companies are investing and partnering. Panel Wed Nov 11 09:00–09:45 Beyond the inhaler: The respiratory market New drugs and targets for asthma, chronic obstructive lung disease and pulmonary fibrosis, and where investors and partners are now putting money. |
Earlybird Venture Capital Berlin, Germany | |
European venture capital firm investing in technology and health companies. | Panel Mon Nov 9 16:00–16:45 Fuelling Innovation: The State of Early-Stage Investment in Biotech Investors and founders discuss how young biotech startups raise early funding today and how venture investors' priorities are shifting. Panel Wed Nov 11 11:00–11:45 AI-Powered Ecosystems: Transforming Drug Discovery Through Digital Collaboration How drug, biotech and tech companies can build AI partnerships, and why AI finds easier wins in early discovery than in later clinical stages. |
European Investment Bank Luxembourg, Luxembourg | |
The European Union's lending institution, providing loans and venture debt, including to life sciences companies. | Panel Tue Nov 10 14:30–14:55 Investing in Women’s Health: How Can Europe Scale Innovation? How Europe can grow investment in women's health, previewing a European Investment Bank study of the field's research, unmet needs and funding options. Panel Tue Nov 10 11:15–12:15 Women’s Health: Healthcare’s Largest Underserved Market and Biggest Growth Opportunity Why women's health is a large, neglected market, and how much value is lost when medicine is designed around the wrong default patient. Therapeutic InsightsBusiness of Biotech |
Flagship Pioneering Cambridge, MA | |
Company-creation firm that founds, builds and funds biotech companies. | Panel Mon Nov 9 17:00–17:45 AI in the Lab: Why Greater Efficiency Could Mean More Drugs, Not Fewer Scientists Whether AI can speed drug development, not just discovery, how it is changing clinical trials, and whether it will replace some scientists. Ecosystem InnovationBusiness of Biotech Panel Wed Nov 11 09:00–09:45 How is the APAC region reshaping global biopharma? How China, Japan, South Korea and other Asia-Pacific countries are moving from making drugs to inventing them, and how Western firms can partner. |
HealthCare Royalty Stamford, CT | |
Royalty and structured-credit investor financing late-stage and commercial biopharmaceutical companies. | Panel Tue Nov 10 16:00–16:45 Capital, Creativity, and Optionality: The New Anatomy of Life Sciences Transactions How biotechs raise money by selling rights to future drug sales, spinning off new companies, or going public by merging with a listed one. Panel Wed Nov 11 11:00–11:45 Funding Outside the Box: Alternative Financing Strategies for Startups Ways biotech startups can raise money besides venture investors, such as loans or selling a share of future sales, and when each fits. |
AP Asabys Partners Barcelona, Spain | |
Venture capital firm investing in healthcare and life sciences companies. | Panel Tue Nov 10 15:00–15:45 Longevity – Are we getting younger? What recent research shows about treatments that could slow or reverse aging, and how investment in this young field is taking shape. |
Seroba Dublin, Ireland | |
European venture capital firm investing in biotech and medtech companies, mainly at seed and Series A. | Panel Mon Nov 9 14:00–14:45 ADCs in oncology: What does the data show? What the latest data show on how well and how safely antibody–drug conjugates treat cancer, and which technologies and targets attract investors. |
Venture capital firm investing in clinical-stage biotherapeutics companies in Europe and the US. | Panel Mon Nov 9 16:15–17:00 Building the Next Global Biotech Hubs: What Makes an Innovation Ecosystem Work? What makes a region a strong biotech hub, from talent, labs and funding to links with global drug companies. |
Venture investor based in Belgium and the US that backs companies developing medicines from new science. | Panel Mon Nov 9 16:00–16:45 Fuelling Innovation: The State of Early-Stage Investment in Biotech Investors and founders discuss how young biotech startups raise early funding today and how venture investors' priorities are shifting. Talk Mon Nov 9 09:00–10:00 Pitch, Present, Persuade: Become a Powerful Corporate Communicator Practical ways to build a personal brand, tell memorable stories, simplify complex messages and give persuasive presentations, in person and on video. |
LifeArc London, United Kingdom | |
UK medical research charity that funds translational research and invests in early-stage life sciences companies through LifeArc Ventures. | Panel Tue Nov 10 16:00–16:45 At the Board Table: Navigating Power Dynamics and Building Senior Stakeholder Trust (In collaboration with YVC) How younger executives and junior investors on biotech boards can earn senior members' trust and help drive decisions. Panel Tue Nov 10 10:00–10:45 Cardiometabolic innovations beyond GLP-1 – Where are we now? Which drug approaches beyond GLP-1 medicines are drawing attention for obesity, diabetes and heart disease risk, and where money and partnerships are going. |
M Ventures Amsterdam, Netherlands | |
Corporate venture capital arm of Merck KGaA, investing in healthcare, life science and electronics start-ups. | Talk Mon Nov 9 15:00–16:15 Merck's EMEA Advance Biotech Grant Program Five young biotech companies pitch their science to Merck, competing for a grant that helps them bring a product to market. Panel Mon Nov 9 11:15–12:00 Unlocking Pharma’s Productivity Potential Why developing medicines keeps getting costlier and slower, and whether AI and research sourced from other companies can make drug companies more productive. Business of Biotech |
Find buyers from investors
Tell us what you sell and we’ll find the people at these investors most likely to buy it.
- Who to contact
- Their contact info
- What to say
- Free, no sign-up
Browse BIO-Europe 2026 by
Organization type
Track
Everyone
Not affiliated with or endorsed by BIO-Europe or its organizers. Submit a correction